National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 2) PB 12 of 2014 (Cth)

PB 12 of 2014

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 2)

National Health Act 1953

___________________________________________________________________________

I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated 23 February 2014

KIM BESSELL

Assistant Secretary

Pharmaceutical Access Branch

Principal Pharmacy Advisor

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________

1              Name of Instrument

(1)This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.2).

(2)This Instrument may also be cited as PB 12 of 2014.

2             Commencement

This Instrument commences on 1 March 2014.

3              Amendments to PB 79 of 2011

Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Schedule 1                   Amendments

1. Schedule 1 Part 1, entry for Carboplatin in the form ‘Solution for I.V. injection 150 mg in 15 mL’ with manner of administration Injection:

omit:     

Pfizer Australia Pty Ltd PF MP D

1. Schedule 1 Part 1, entry for Cisplatin in the forms ‘I.V. injection 100 mg in 100 mL’ and ‘I.V. injection 50 mg in 50 mL’ with manner of administration Injection:

omit:     

Pfizer Australia Pty Ltd PF MP D

1. Schedule 1 Part 1, entry for Epirubicin in the form ‘Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL’ with manner of administration Injection/Intravesical:

omit:

Epirubicin Kabi PK MP D

1. Schedule 1 Part 1, entry for Fludarabine in the form ‘Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL’ with manner of administration Injection:

omit:

Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL	Injection	AS‑Fludarabine	YA	MP	C3887	PB
insert:	Fludarabine Ebewe	SZ	MP	C3887	PB
Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL	Injection	Fludarabine-Ebewe	SZ	MP	C3887	PB

1. Schedule 1 Part 1, entry for Gemcitabine in the forms ‘Powder for I.V. infusion 2 g (as hydrochloride)’ and ‘Powder for I.V. infusion 200 mg (as hydrochloride)’  with manner of administration Injection:

omit:     

Gemcitabine Kabi PK MP D

1. Schedule 1 Part 1, entry for Gemcitabine in the form ‘Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL’ with the manner of administration Injection :

omit:

Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL	Injection	Gemcitabine AS	YA	MP	D
Gemcitabine Ebewe	SZ	MP	D

insert:

Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL Injection Gemcitabine Ebewe SZ MP D

1. Schedule 1 Part 1, entry for Gemcitabine in the form ‘Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL’ with the manner of administration Injection :

omit:

Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL	Injection	Gemcitabine AS	YA	MP	D
Gemcitabine Ebewe	SZ	MP	D

insert:

Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL Injection Gemcitabine Ebewe SZ MP D

1. Schedule 1 Part 1, entry for Irinotecan in the form ‘I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL’ with the manner of administration Injection :

omit:     

Irinotecan Kabi PK MP C3184 D

1. Schedule 1 Part 1, entry for Mitozantrone in the form ‘Injection 20 mg (as hydrochloride) in 10 mL’ with the manner of administration Injection :

omit:     

Pfizer Australia Pty Ltd PF MP D

[10]  Schedule 1 Part 1, entry for Oxaliplatin in the form ‘Solution concentrate for I.V. infusion 50 mg in 10 mL’ with the manner of administration Injection :

omit:     

Oxaliplatin Kabi PK MP C3900 C3901 C3930 C3939 D

[11]  Schedule 1 Part 1, entry for Paclitaxel in the form ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’ with the manner of administration Injection :

omit:     

Paclitaxel Kabi PK MP C3186 C3890 C3902 C3917  C3955 C3956 D

[12]  Schedule 1 Part 1, entry for Paclitaxel in the forms ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’; ‘Solution concentrate for I.V. infusion 30 mg in 5 mL’ and ‘Solution concentrate for I.V. infusion 300 mg in 50 mL’ with the manner of administration Injection :

omit:     

Taxol BQ MP C3186 C3890 C3902 C3917  C3955 C3956 D